STI571

An inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia

Michael E. O'Dwyer, Brian Druker

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The deregulated tyrosine kinase activity of the BCR-ABL fusion protein has been established as the causative molecular event in chronic myelogenous leukaemia. Thus, the BCR-ABL tyrosine kinase is an ideal target for pharmacological inhibition. STI571 (formerly CGP57148B), is an ABL-specific inhibitor of tyrosine kinase that, in preclinical studies, selectively killed BCR-ABL-containing cells in vitro and in vivo. Clinical studies have shown the potential of this specifically targeted therapy, and STI571 is emerging as an important new therapeutic agent for chronic myelogenous leukaemia.

Original languageEnglish (US)
Pages (from-to)207-211
Number of pages5
JournalLancet Oncology
Volume1
Issue number4
StatePublished - Dec 1 2000

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Pharmacology
Therapeutics
Imatinib Mesylate
Proteins

ASJC Scopus subject areas

  • Oncology

Cite this

STI571 : An inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. / O'Dwyer, Michael E.; Druker, Brian.

In: Lancet Oncology, Vol. 1, No. 4, 01.12.2000, p. 207-211.

Research output: Contribution to journalArticle

@article{52fa71a0b4de4887a88b4e19769cf1eb,
title = "STI571: An inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia",
abstract = "The deregulated tyrosine kinase activity of the BCR-ABL fusion protein has been established as the causative molecular event in chronic myelogenous leukaemia. Thus, the BCR-ABL tyrosine kinase is an ideal target for pharmacological inhibition. STI571 (formerly CGP57148B), is an ABL-specific inhibitor of tyrosine kinase that, in preclinical studies, selectively killed BCR-ABL-containing cells in vitro and in vivo. Clinical studies have shown the potential of this specifically targeted therapy, and STI571 is emerging as an important new therapeutic agent for chronic myelogenous leukaemia.",
author = "O'Dwyer, {Michael E.} and Brian Druker",
year = "2000",
month = "12",
day = "1",
language = "English (US)",
volume = "1",
pages = "207--211",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "4",

}

TY - JOUR

T1 - STI571

T2 - An inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia

AU - O'Dwyer, Michael E.

AU - Druker, Brian

PY - 2000/12/1

Y1 - 2000/12/1

N2 - The deregulated tyrosine kinase activity of the BCR-ABL fusion protein has been established as the causative molecular event in chronic myelogenous leukaemia. Thus, the BCR-ABL tyrosine kinase is an ideal target for pharmacological inhibition. STI571 (formerly CGP57148B), is an ABL-specific inhibitor of tyrosine kinase that, in preclinical studies, selectively killed BCR-ABL-containing cells in vitro and in vivo. Clinical studies have shown the potential of this specifically targeted therapy, and STI571 is emerging as an important new therapeutic agent for chronic myelogenous leukaemia.

AB - The deregulated tyrosine kinase activity of the BCR-ABL fusion protein has been established as the causative molecular event in chronic myelogenous leukaemia. Thus, the BCR-ABL tyrosine kinase is an ideal target for pharmacological inhibition. STI571 (formerly CGP57148B), is an ABL-specific inhibitor of tyrosine kinase that, in preclinical studies, selectively killed BCR-ABL-containing cells in vitro and in vivo. Clinical studies have shown the potential of this specifically targeted therapy, and STI571 is emerging as an important new therapeutic agent for chronic myelogenous leukaemia.

UR - http://www.scopus.com/inward/record.url?scp=0034584880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034584880&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 207

EP - 211

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 4

ER -